“Stapling” scFv for multispecific biotherapeutics of superior properties

References

• Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1. doi:10.1186/s12929-019-0592-z. PMID: 31894001.
   PubMed Web of Science ®Google Scholar
• Senior M. Fresh from the biotech pipeline: fewer approvals, but biologics gain share. Nat Biotechnol. 2023;41:174–15. doi:10.1038/s41587-022-01630-6. PMID: 36624153.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. mAbs. 2023;15:2153410. doi:10.1080/19420862.2022.2153410. PMID: 36472472.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185:2789–805. doi:10.1016/j.cell.2022.05.029. PMID: 35868279.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9:182–212. doi:10.1080/19420862.2016.1268307. PMID: 28071970.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. Bispecific antibodies. Science. 2021;372:916–17. doi:10.1126/science.abg1209.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608. doi:10.1038/s41573-019-0028-1.
   PubMed Web of Science ®Google Scholar
• June CH, O’connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–65. doi:10.1126/science.aar6711.
   PubMed Web of Science ®Google Scholar
• Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M. Single-chain antigen-binding proteins. Science. 1988;242:423–26. PMID: 3140379 http://www.ncbi.nlm.nih.gov/pubmed/3140379.
   PubMed Web of Science ®Google Scholar
• Rothlisberger D, Honegger A, Pluckthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol. 2005;347:773–89. doi:10.1016/j.jmb.2005.01.053. PMID: 15769469.
   PubMed Web of Science ®Google Scholar
• Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol. 2001;305:989–1010. doi:10.1006/jmbi.2000.4265. PMID: 11162109.
   PubMed Web of Science ®Google Scholar
• Fenn S, Schiller CB, Griese JJ, Duerr H, Imhof-Jung S, Gassner C, Moelleken J, Regula JT, Schaefer W, Thomas M, et al. Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. PLoS One. 2013;8:e61953. PMID: 23613981. doi:10.1371/journal.pone.0061953.
   PubMed Web of Science ®Google Scholar
• Long NE, Sullivan BJ, Ding H, Doll S, Ryan MA, Hitchcock CL, Martin EW Jr., Kumar K, Tweedle MF, Magliery TJ. Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging. J Biol Chem. 2018;293:9030–40. doi:10.1074/jbc.RA118.002538. PMID: 29669811.
   PubMed Web of Science ®Google Scholar
• Toughiri R, Wu X, Ruiz D, Huang F, Crissman JW, Dickey M, Froning K, Conner EM, Cujec TP, Demarest SJ. Comparing domain interactions within antibody Fabs with kappa and lambda light chains. mAbs. 2016;8:1276–85. doi:10.1080/19420862.2016.1214785. PMID: 27454112.
   PubMed Web of Science ®Google Scholar
• Roberts CJ. Protein aggregation and its impact on product quality. Curr Opin Biotechnol. 2014;30:211–17. doi:10.1016/j.copbio.2014.08.001. PMID: 25173826.
   PubMed Web of Science ®Google Scholar
• Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schoneich C, Winter G, Friess W, Crommelin DJ, Carpenter JF. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci. 2012;101:946–54. doi:10.1002/jps.23018. PMID: 22170395.
   PubMed Web of Science ®Google Scholar
• Pham NB, Meng WS. Protein aggregation and immunogenicity of biotherapeutics. Int J Pharm. 2020;585:119523. doi:10.1016/j.ijpharm.2020.119523. PMID: 32531452.
   PubMedGoogle Scholar
• Arndt KM, Muller KM, Pluckthun A. Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain. J Mol Biol. 2001;312:221–28. doi:10.1006/jmbi.2001.4915. PMID: 11545598.
   PubMed Web of Science ®Google Scholar
• Asial I, Cheng YX, Engman H, Dollhopf M, Wu B, Nordlund P, Cornvik T. Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell. Nat Commun. 2013;4:2901. doi:10.1038/ncomms3901. PMID: 24352381.
   PubMed Web of Science ®Google Scholar
• Gil D, Schrum AG. Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. Advances in bioscience and biotechnology. 2013;4:73–84. 10.4236/abb.2013.44A011. PMID: 25635232.
   Google Scholar
• Monsellier E, Bedouelle H. Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms. J Mol Biol. 2006;362:580–93. doi:10.1016/j.jmb.2006.07.044. PMID: 16926023.
   PubMed Web of Science ®Google Scholar
• Perchiacca JM, Tessier PM. Engineering aggregation-resistant antibodies. Annual review of chemical and biomolecular engineering. Annu Rev Chem Biomol Eng. 2012;3:263–86. PMID: 22468604. doi:10.1146/annurev-chembioeng-062011-081052.
   PubMed Web of Science ®Google Scholar
• Tiller KE, Tessier PM. Advances in Antibody Design. Annu Rev Biomed Eng. 2015;17:191–216. doi:10.1146/annurev-bioeng-071114-040733. PMID: 26274600.
   PubMed Web of Science ®Google Scholar
• Zhao JX, Yang L, Gu ZN, Chen HQ, Tian FW, Chen YQ, Zhang H, Chen W. Stabilization of the single-chain fragment variable by an interdomain disulfide bond and its effect on antibody affinity. Int J Mol Sci. 2010;12:1–11. doi:10.3390/ijms12010001. PMID: 21339972.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A. 1993;90:7538–42. doi:10.1073/pnas.90.16.7538. PMID: 8356052.
   PubMed Web of Science ®Google Scholar
• Jung SH, Pastan I, Lee B. Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins. 1994;19:35–47. doi:10.1002/prot.340190106. PMID: 8066084.
   PubMed Web of Science ®Google Scholar
• Kugler M, Stein C, Schwenkert M, Saul D, Vockentanz L, Huber T, Wetzel SK, Scholz O, Pluckthun A, Honegger A, et al. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel. 2009;22:135–47. PMID: 19188138. doi:10.1093/protein/gzn079.
   PubMed Web of Science ®Google Scholar
• Schaefer JV, Pluckthun A. Transfer of engineered biophysical properties between different antibody formats and expression systems. Protein Eng Des Sel. 2012;25:485–506. doi:10.1093/protein/gzs039. PMID: 22763265.
   PubMed Web of Science ®Google Scholar
• Weatherill EE, Cain KL, Heywood SP, Compson JE, Heads JT, Adams R, Humphreys DP. Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation. Protein Eng Des Sel. 2012;25:321–29. doi:10.1093/protein/gzs021. PMID: 22586154.
   PubMed Web of Science ®Google Scholar
• Nesspor TC, Kinealy K, Mazzanti N, Diem MD, Boye K, Hoffman H, Springer C, Sprenkle J, Powers G, Jiang H, et al. High-Throughput generation of bipod (Fab × scFv) bispecific antibodies exploits differential chain expression and affinity capture. Sci Rep. 2020;10:7557. PMID: 32372058. doi:10.1038/s41598-020-64536-w.
   PubMed Web of Science ®Google Scholar
• Spreter Von Kreudenstein T, Lario PI, Dixit SB. Protein engineering and the use of molecular modeling and simulation: the case of heterodimeric Fc engineering. Methods. 2014;65:77–94. doi:10.1016/j.ymeth.2013.10.016. PMID: 24211748.
   PubMed Web of Science ®Google Scholar
• Fransson J, Teplyakov A, Raghunathan G, Chi E, Cordier W, Dinh T, Feng Y, Giles-Komar J, Gilliland G, Lollo B, et al. Human framework adaptation of a mouse anti-human IL-13 antibody. J Mol Biol. 2010;398:214–31. PMID: 20226193. doi:10.1016/j.jmb.2010.03.004.
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol. 1987;196:901–17. doi:10.1016/0022-2836(87)90412-8. PMID: 3681981.
   PubMed Web of Science ®Google Scholar
• Scapin G, Yang X, Prosise WW, McCoy M, Reichert P, Johnston JM, Kashi RS, Strickland C. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol. 2015;22:953–58. doi:10.1038/nsmb.3129. PMID: 26595420.
   PubMed Web of Science ®Google Scholar
• Harris LJ, Larson SB, Hasel KW, McPherson A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry. 1997;36:1581–97. doi:10.1021/bi962514. PMID: 9048542.
   PubMed Web of Science ®Google Scholar
• Zhang RM, Snyder GH. Dependence of formation of small disulfide loops in two-cysteine peptides on the number and types of intervening amino acids. J Biol Chem. 1989;264:18472–79. PMID: 2808384 https://www.ncbi.nlm.nih.gov/pubmed/2808384.
   PubMed Web of Science ®Google Scholar
• Shi L, Wheeler JC, Sweet RW, Lu J, Luo J, Tornetta M, Whitaker B, Reddy R, Brittingham R, Borozdina L, et al. De Novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins. J Mol Biol. 2010;397:385–96. PMID: 20114051. doi:10.1016/j.jmb.2010.01.034.
   PubMed Web of Science ®Google Scholar
• Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RA, Needham MR, Langham C, Barker W, Aziz A, Snow MJ, et al. Structure of IL-17A in complex with a potent, fully human neutralizing antibody. J Mol Biol. 2009;394:905–21. doi:10.1016/j.jmb.2009.10.008. pii PMID: 19835883.
   PubMed Web of Science ®Google Scholar
• Alberola-Ila J, Places L, de la Calle O, Romero M, Yague J, Gallart T, Vives J, Lozano F. Stimulation through the TCR/CD3 complex up-regulates the CD2 surface expression on human T lymphocytes. J Immunol. 1991;146:1085–92. PMID: 1671400 https://www.ncbi.nlm.nih.gov/pubmed/1671400.
   PubMed Web of Science ®Google Scholar
• Teplyakov A, Obmolova G, Malia TJ, Luo J, Muzammil S, Sweet R, Almagro JC, Gilliland GL. Structural diversity in a human antibody germline library. mAbs. 2016;8:1045–63. doi:10.1080/19420862.2016.1190060. PMID: 27210805.
   PubMed Web of Science ®Google Scholar
• Pessano S, Oettgen H, Bhan AK, Terhorst C. The T3/T cell receptor complex: antigenic distinction between the two 20-kd T3 (T3-delta and T3-epsilon) subunits. Embo J. 1985;4:337–44. PMID: 2410254 https://www.ncbi.nlm.nih.gov/pubmed/2410254.
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617–21. doi:10.1093/protein/9.7.617. PMID: 8844834.
   PubMedGoogle Scholar
• Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, Uchida M, Kofman E, Raoufi F, Motlagh S, et al. Predicting antibody developability profiles through early stage discovery screening. mAbs. 2020;12:1743053. PMID: 32249670. doi:10.1080/19420862.2020.1743053.
   PubMed Web of Science ®Google Scholar
• Gekko K, Kimoto A, Kamiyama T. Effects of disulfide bonds on compactness of protein molecules revealed by volume, compressibility, and expansibility changes during reduction. Biochemistry. 2003;42:13746–53. doi:10.1021/bi030115q. PMID: 14622021.
   PubMed Web of Science ®Google Scholar
• Betz SF. Disulfide bonds and the stability of globular proteins. Protein Sci. 1993;2:1551–58. doi:10.1002/pro.5560021002. PMID: 8251931.
   PubMed Web of Science ®Google Scholar
• Dani VS, Ramakrishnan C, Varadarajan R. MODIP revisited: re-evaluation and refinement of an automated procedure for modeling of disulfide bonds in proteins. Protein Eng. 2003;16:187–93. doi:10.1093/proeng/gzg024. PMID: 12702798.
   PubMedGoogle Scholar
• Kabsch W. Xds. Acta crystallographica section D, biological crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:125–32. PMID: 20124692. doi:10.1107/S0907444909047337.
   PubMed Web of Science ®Google Scholar
• Collaborative Computational Project N. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994;53:240–55. doi:10.1107/S0907444994003112.
   Google Scholar
• Read RJ. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr. 2001;57:1373–82. PMID: 11567148 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11567148.
   PubMedGoogle Scholar
• Adams PD, Gopal K, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Pai RK, Read RJ, Romo TD, et al. Recent developments in the PHENIX software for automated crystallographic structure determination. J Synchrotron Radiat. 2004;11:53–55. http://scripts.iucr.org/cgi-bin/paper?S090904950302413010.1107/S0909049503024130
   PubMed Web of Science ®Google Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486–501. doi:10.1107/S0907444910007493. PMID: 20383002.
   PubMed Web of Science ®Google Scholar